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Abstract
Background: Chronic fatigue syndrome (CFS) is a medically unexplained syndrome for which no somatic or
pharmacological treatment has been proven effective. Dysfunction of the cytokine network has been suspected to
play a role in the pathophysiology of CFS. The disturbances of the cytokine network detected in CFS patients are
highly variable, in part due to the lack of adequate controls in many studies. Furthermore, all studies have been
performed on peripheral venous blood of patients. As cytokines mainly act in tissues, for example, the brain, the
information that can be derived from peripheral blood cells is limited. The information regarding the possible role of
cytokines in the pathophysiology could come from intervention studies in which the activities of relevant cytokines are
reduced, for example, reducing interleukin-1, interleukin-6 or tumor necrosis factor. In this study, the clinical usefulness of
anakinra, an IL-1 antagonist, will be assessed in patients with CFS.
Methods/Design: A randomized placebo-controlled, double-blind trial will be conducted. Fifty adult female patients
meeting the Centers for Disease Control (CDC) criteria for CFS and without psychiatric co-morbidity will be included. After
inclusion, patients will be randomized between treatment with anakinra (recombinant human interleukin-1 receptor
antagonist) or placebo. Each group will be treated for 4 weeks. Outcome measures will be assessed at baseline, after
4 weeks of intervention, and 6 months after baseline assessment. The primary outcome measure will be fatigue
severity at 4 weeks, measured with the validated Checklist of Individual Strength (CIS). Secondary outcome measures
are functional impairment, physical and social functioning, psychological distress, pain severity, presence of
accompanying symptoms, and cytokine and cortisol concentrations.
Discussion: This is the first randomized placebo-controlled trial that will evaluate the effect of interference
with IL-1 on the experience of fatigue in patients with CFS. The results of this study may expand treatment
options for patients with CFS, for whom graded exercise therapy and cognitive behavioral therapy are the
only evidence-based interventions that exist at this moment.
Trial registration: Clinicaltrials.gov: NCT02108210. Clinicaltrials.gov registration date: 8 April 2014. EudraCT:
2013-005466-19
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Background
Chronic fatigue syndrome (CFS) is a medically unex-
plained syndrome characterized by severe disabling
fatigue for a period of at least 6 months, which leads
to considerable impairment in daily functioning [1].
Various accompanying symptoms may be present,
such as headache, joint and muscle pain, sore throat,
impaired memory and concentration and exercise
intolerance. In the Netherlands, the prevalence of
CFS is at least 27,000 persons [2]. So far, the cause
for CFS is yet unclear [3]. Cognitive behavioral ther-
apy (CBT) and graded exercise therapy (GET) are
the only interventions that have shown positive re-
sults in randomized controlled clinical trials for
treating fatigue-associated CFS symptoms and dis-
ability [4–8].
Cytokines are hormone-like proteins that convey
messages between cells. Originally, they were thought to
act only within the host defense system, but soon it be-
came clear that they mediate an array of diverse effects
in normal physiology and disease. Since proinflammatory
cytokines play a key role in inflammation (for example,
by causing fever, inducing muscle pain, fatigue, sleep
and other flu like symptoms), they have been hypothe-
sized to be responsible for the symptoms in CFS [9, 10].
Several studies have been performed to investigate
whether there is an excess of cytokines in CFS, but
so far, findings are inconsistent [11, 12]. A recent sys-
tematic review on circulating cytokines in CFS re-
ported that the majority of studies performed during
the past years did not find significantly increased con-
centrations of proinflammatory cytokines [13]. A
major problem is that many studies did not use ad-
equate controls and used different methods to handle
blood samples. Cytokine responses are under genetic
control, but they are extremely vulnerable to other in-
fluences, such as hormonal status, food, exercise,
stress, behavior, drugs and vaccines [14]. Therefore, it
is not easy to compose a good control group. An
additional problem is that almost all studies have
been performed on peripheral venous blood. As cyto-
kines mainly act in tissues, with the brain being the
most important target organ in CFS, information that
can be derived from studying circulating cytokine
concentrations (which are generally in the pg/ml
range) is limited. The only information regarding a
role of cytokines that is pathophysiologically relevant
could come from intervention studies in which crucial
cytokines in tissue are inhibited. A potentially relevant
cytokine, which can be blocked in humans without
severe side effects, is interleukin-1 (IL-1) [15].
Although it is plausible that cytokines play a role in
the pathophysiology of CFS, there is only indirect
evidence for this theory:
1. The complaints of patients with CFS are often
described as that of a persistent flu. During infections
like influenza, symptoms are generally ascribed to the
action of cytokines (like IL-1, IL-6, tumor necrosis
factor alpha (TNF) and interferons) [9].
2. Many disease states are accompanied by anorexia,
loss of interest, somnolence and fatigue, a
symptom complex coined as sickness behavior.
The cytokines IL-1beta, TNF and IL-6 are thought
to be responsible for it. Administration of either
IL-1, IL-6, TNF or each of the interferons to
humans and animals is accompanied by flu-like
symptoms [16–18].
3. Previously, it was reported that IL-8 and IL-10
were significantly elevated in the cerebrospinal
fluid in patients with CFS, compatible with induc-
tion of IL-1 [19].
4. Beta amyloid precursor protein has also been
found to be elevated in the cerebrospinal fluid of
CFS patients [20]. Production of this protein is
under control of IL-1 and TNF [21–23].
5. Our group has previously established that patients
with CFS have a significant loss of gray matter in
the brain [24, 25]. This loss of gray matter might
be caused by enhanced cytokine activity.
Drugs that interfere with the proinflammatory cyto-
kine IL-1 are commonly used nowadays for a variety
of inflammatory disorders [26]. The recombinant IL-1
receptor antagonist (anakinra) reduces the activity of
both IL-1α and IL-1ß by binding to the IL-1 receptor.
This intervention is highly targeted and hence would
allow investigators to draw conclusions regarding the
pathophysiology of CFS, and the effect of reducing
cytokine concentrations in CFS patients. Moreover,
compared to blocking TNF-α or IL-6, blocking IL-1
with anakinra has a long safety recorded with respect
to side effects, and is not associated with increased
susceptibility to opportunistic infections such as
Mycobacterium tuberculosis.
The primary aim of this study is to assess the effect
of anakinra on fatigue severity in patients with CFS.
Fatigue is the most central and characterizing symp-
tom of CFS, and in contrast to the accompanying
symptoms, it is reported by all patients. It is also
strongly related to the functional impairments re-
ported by patients. As a secondary study aim, we will
assess the effect of anakinra on the level of functional
impairment, physical and social functioning, pain se-
verity, presence of accompanying symptoms and psy-
chological distress. In this paper, we describe the
protocol to evaluate the effects of anakinra. Other
studies with anakinra or anti-IL-1ß revealed a de-
crease in fatigue [27–30].
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Methods/Design
Study design
A randomized placebo-controlled trial (RCT) will be
performed to determine whether interference with IL-1
is able to reduce fatigue and disabilities in CFS patients.
Within each study arm, treatment will be double blind.
The study will be performed in the Radboud University
Medical Center, in the Department of Internal Medicine
and in the Expert Center for Chronic Fatigue (ECCF),
located in Nijmegen, the Netherlands. All female CFS
patients visiting the outpatient clinic of the department
of Internal Medicine or visiting the ECCF will be consid-
ered for participation. Furthermore, patients connected
to the “ME/CVS-stichting,” a Dutch foundation for CFS
patients, will be asked to participate in the study. To in-
crease homogeneity in our study population, we decided
to only include female patients, as CFS is a disease that
mostly affects women. After inclusion, each patient will
receive an individual study code. Patients will be asked
to bring a healthy, age-matched, neighborhood control
to their first study visit. If patients decide not to partici-
pate in this study, an attempt will be made to elucidate
the reason for this, but patients are not obligated to
explain their refusal.
Study population
Fifty subsequent patients will be included and equally
randomized between treatment arms. Inclusion criteria
for participation comprise the CDC diagnosis of CFS
[20, 31], fatigue duration ≤ 10 years or recent progres-
sion of fatigue severity, female sex, age between 18 and
59 years old, a score ≥ 40 on the subscale fatigue severity
of the Checklist of Individual Strength (CIS), and a
score ≥ 700 on the Sickness Impact Profile (SIP). The ex-
clusion criteria include females who are pregnant or
nursing, intend to get pregnant during the study, use or
have used psychotropic medication in the past month,
received a live vaccine during the last 4 weeks, had sub-
stance abuse in the past 3 months, have had symptoms
more than 10 years, are taking any medication except
oral contraceptives and/or paracetamol, have evident
somatic comorbidity, have current engagement in CFS
research, do not have the ability to understand the na-
ture and the extent of the trial and the procedure re-
quired, have psychiatric comorbidity (major depression,
psychosis, eating disorders, anxiety disorders, bipolar
disease and post-traumatic stress disorder) assessed with
‘The Mini-International Neuropsychiatric Interview’
(M.I.N.I.) [32], or are currently engaged in a legal pro-
cedure with respect to disability claims.
Ethical approval
The study is approved by the Medical Ethical Review
Committee of the Radboud UMC Nijmegen (registration
number 2014/025). The study is registered at the Euro-
pean Union Drug Regulating Authorities (EudraCT:
2013–005466–19) and will be conducted according to
the Declaration of Helsinki, Good Clinical Practice
(GCP) and Good Manufacturing Practice (GMP) guide-
lines. The inclusion of patients started in July 2014.
Written informed consent will be obtained from all pa-
tients before participation in the trial.
Study medication, randomization and follow-up
Eligibility for participation of patients is determined at
the pre-study visit. After giving informed consent, pa-
tients will be screened for inclusion and exclusion cri-
teria by means of the examinations listed in Fig. 1.
Laboratory investigations performed earlier will be eval-
uated for all patients and will be repeated if not per-
formed recently, or when essential measurements, as
recommended by others [31], are missing. Patients who
qualify to be included will be randomized 1:1 to receive
either anakinra (100 mg/day) or placebo. Randomization
will be performed by the study pharmacist (Department
of Clinical Pharmacology, Radboud University Medical
Center), will be known only by the pharmacist and will
be exposed only in case of emergency. If the code is
broken, it will render the participant not eligible. When
the study is completed, the randomization list will be
made available by the study pharmacist.
Study medication will be provided by the Swedish Or-
phan Biovitrium (Sobi) and stored at the Department of
Pharmacology of the RadboudUMC. Preparation and la-
belling of anakinra and placebo will be done according
to the current guidelines. This will be performed by the
Clinical Trials Unit department of Clinical Pharmacol-
ogy of the RadboudUMC. The anakinra and placebo sy-
ringes will be identical in appearance; the placebo
syringes will contain a mixture of sodium citrate, sodium
chloride and polysorbate. Medication is used once daily,
during a period of 4 weeks. The anakinra and placebo
will be provided by the main investigator. On the first
study day, patients will be instructed how to self-inject
the study medication, as described by others [27]. Ad-
ministration takes place in the subcutaneous tissue, most
often the abdomen or the thighs. During the study, pa-
tients will be advised to set their alarm clock daily at the
same time to remind them to use the medication cor-
rectly. Drug adherence will be evaluated after 1 week
and after completion of treatment. Patients will return
all used and unused syringes after 4 weeks.
During the intervention period, use of co-medication
is only allowed when used for ≤ 14 consecutive days and
on the condition that there are no known interactions
with anakinra. Oral contraceptives and/or paracetamol
can be used without limitation. During the follow-up
period, there are no limitations regarding the use of
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Fig. 1 Study-specific procedures
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medication. All co-medication will be registered and re-
ported afterwards.
Since the anakinra arm is difficult to blind because of
local reactions at the injection site, the research phys-
ician and the principal investigator will not be informed
of the side effects. After the injection instruction by the
physician assistant (PA), the patient will be instructed to
report adverse effects to the PA and not to the research
physician. The PA will report all side effects to an inde-
pendent physician. The independent physician will
examine patients if needed and is mandated to stop
treatment. To evaluate blinding of the treatment, pa-
tients will be asked which medication they thought they
were using during the trial, after they have completed
the study.
Study visits are carried out at week 0, week 4 and, if
needed, after 6 months. After 1 week, patients will be
contacted by telephone to evaluate the occurrence of
any problems regarding the use of medication and drug
utilization will be recorded. If there are serious side ef-
fects, an additional study visit can be performed by the
independent physician at any time. Between study visits,
subjects will be asked to fill out web-based question-
naires up to 6 months after their first study visit (Fig. 1).
Outcome measures
The primary outcome measure is fatigue severity mea-
sured with the subscale fatigue severity of the Checklist
of Individual Strength (CIS) at 4 weeks, the primary end-
point of the study. Scores on the CIS subscale range
from 8 to 56 (8 items, 7-point Likert Scale). This ques-
tionnaire has been validated extensively in patients with
chronic fatigue syndrome [33, 34]. Patients will fill out
this web-based questionnaire weekly during the course
of the trial and monthly during the follow-up period
(Fig. 1).
Secondary outcome measures
Secondary outcome measures:
1. Level of functional impairment. The level of functional
impairment will be measured with the Sickness Impact
Profile (SIP8) total score. The SIP8 is a validated
instrument to evaluate sickness-related dysfunction.
The total score gives an indication of the experienced
disabilities in all domains of functioning [35].
2. Physical and social functioning. Physical and social
functioning will be assessed with the subscale
physical functioning and subscale social functioning
of the Short Form (SF)-36 [36].
3. Level of psychological distress. The level of
psychological distress will be assessed with the total
score on the Symptom Checklist-90 (SCL-90). A
high total score reflects psychological distress [37].
4. Pain severity. Pain severity will be assessed with a
visual analog scale (VAS). This score can vary between
0 (no pain) and 10 (worst pain ever experienced).
5. Presence of accompanying symptoms. The presence
of accompanying symptoms will be evaluated using
the CDC criteria. The number of symptoms can
vary between 0 and 8.
6. Cytokine concentration in blood. The cytokine
concentrations in blood (plasma and blood in Pax-
gene tubes) will be determined. Our study can pro-
vide additional information regarding cytokine levels
because we have the opportunity to compare cyto-
kine concentrations with healthy neighborhood con-
trols. Also we will compare pre-treatment
concentrations with post-treatment concentrations.
7. Cortisol concentration in hair and saliva. Cortisol
concentrations in hair and saliva will be assessed
because of the possible role of the hypothalamus-
pituitary-adrenal axis in CFS. For the baseline assess-
ment, comparison will be made with cortisol con-
centrations in matched neighborhood controls. All
patients will collect saliva for 2 consecutive days at
four different time points (directly after awakening,
30 min after awakening, 11 a.m., 8 p.m.), using the
passive drool method. Saliva will be stored at -80 °C
until further analysis.
8. Microbiome determination in stools. This will give
more insight into the microbial flora of the host,
which is a new field of interest in a wide range of
diseases. The availability of well-defined patients
with CFS and matched controls is a great opportun-
ity in an unexplored area of CFS research to assess
whether the microbiome of CFS patients is peculiar.
Patients will collect feces at home, and all samples
will be stored at –80 °C until further analysis.
All secondary outcome measures will be assessed at
baseline and directly following the intervention (Fig. 1).
Only the VAS pain scale will be filled in weekly (together
with the CIS) during the trial.
At 6 months, all questionnaires evaluating primary
and secondary outcomes will be repeated to evaluate if
the expected effects of the medication are maintained
during the follow-up period of 5 months.
Other study parameters collected at baseline will in-
clude the following: demographic data, medical history,
psychiatric history, serology results collected before in-
clusion in the study, use of medication, smoking and the
use of alcohol and drugs.
Withdrawal of individual participants
Subjects can leave the study at any time for any reason if
they wish to do so without any consequences. The inves-
tigator or independent physician can decide to withdraw
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a subject from the study for urgent medical reasons. In
general, noncompleters are not to be replaced. Subjects
withdrawn from the study for a medical reason or ad-
verse event will receive adequate follow-up. All analysis
will be done according to the Intention-to-Treat
principle (ITT). In case of discontinuation, efforts will
be made to continue all study measurements. With-
drawn patients, or patients who are still severely fatigued
following the intervention, will be offered regular care,
which is CBT at the ECCF.
Adverse events
Adverse events (AE) are defined as any undesirable ex-
perience occurring to a subject during the study,
whether or not considered related to the investigational
product. All adverse events reported spontaneously by
the subject or observed by the investigator or his staff
will be recorded. Anakinra is known as a very safe drug.
Side effects are mainly related to irritation at the injec-
tion site, these reactions usually wane with prolonged
treatment. We have reported from our own experience
with long-term use of anakinra in patients with Schnitz-
ler syndrome that the risk for infection is not enhanced,
even in this elderly group [38]. Nevertheless, the package
insert warns against infectious complications in patients
with underlying illness. Rarely, neutropenia develops
during treatment, which is a reason to discontinue
therapy.
Statistical analysis
The primary analysis will be the comparison between
the two different treatment groups (anakinra or placebo)
at 4 weeks. Data will be analyzed on an ITT basis. Miss-
ing values will be replaced using multiple imputation
with fully conditional specification with at least five im-
putations. The imputation method that will be used is
predictive mean matching for missing data in primary
and secondary outcome measures. Aside from condition,
we will use the following variables assessed at baseline
to generate the imputations: duration of symptoms, age,
BMI and baseline values of the outcome measures.
The results will be analyzed with SPSS for Windows.
To determine if there is a significant difference between
the intervention arm and placebo condition, ANCOVA
will be used with the outcome measure on the second
assessment as the dependent measure, the baseline score
as the covariate, and condition as the fixed factor [39].
We will test if significant differences exist between both
groups in mean age and BMI at baseline, both known to
influence circulating cytokine levels. If so, these variables
will be entered as covariates in the ANCOVA. When a
statistically significant difference is found in the primary
analysis, a sensitivity analysis will be performed on the
basis of different assumptions about the values of
missing data. For the secondary outcome measures, the
same analysis will be repeated, but the secondary out-
come measures at the second assessment will serve as
the dependent variable and the scores at baseline as the
covariate.
Power calculation
The sample size is based on the fatigue subscale score of
the CIS at 4 weeks. In the present study, the power cal-
culation is based on results from comparable studies
with CFS patients where fatigue severity was determined
with the CIS-fatigue scale [40]. If interleukin-1 plays a
central role in CFS symptomatology, we expect a consid-
erable reduction of fatigue following treatment. Assum-
ing a large controlled effect size of 0.85, an alpha of 0.05
and a power of 0.80, 23 patients are needed in each arm
of the study. The number of patients can be further re-
duced by using ANCOVA, with the outcome measure
on the second assessment as the dependent measure,
the baseline score as the covariate, and condition as the
fixed factor. In this kind of trials, ANCOVA yields
greater power compared to other statistical methods
[39]. Based on the correlation between the pre- and post
CIS fatigue scale, the sample size of 23 can be multiplied
by 0.883 (1 to 0.3422). Including an assumed dropout
rate of 20 percent, we will have to include 25 patients in
each group to demonstrate a significant difference be-
tween the medication group and placebo.
Discussion
This study will be the first randomized placebo-
controlled trial to evaluate the effect of blocking IL-1 on
symptoms in patients with CFS. Earlier studies investi-
gated cytokine production to be of relevance in CFS pa-
tients, but conflicting results have been published [11,
13]. A possible explanation is that good controls have
not been used in these studies, and cytokines were mea-
sured in peripheral blood instead of in tissues.
Blinding the study for anakinra is a difficult proced-
ure because of the occurrence of local skin reactions
in a significant amount of patients. To maintain the
double-blind design of this trial, side effects will be
evaluated by an independent PA. In earlier “double
blind” trials, medication was injected in the presence
of the main investigator [27]. The effect of anakinra
will be measured up to 6 months after the start of
treatment. In this manner, we can evaluate the long-
term effect of blocking IL-1 for a short period. It will
provide more insight into the best treatment for CFS
patients when blocking IL-1 appears to be effective.
In conclusion, this study will provide more insight into
the pathophysiology and treatment of patients with CFS.
If an effective treatment can be found, this will
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drastically improve the quality of life in patients with
this disabling disease.
Trial status
Recruiting.
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